Adaptimmune Therapeutics PLC Sponsored ADR ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für Adaptimmune Therapeutics PLC Sponsored ADR zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um Adaptimmune Therapeutics PLC Sponsored ADR zu Deinem Portfolio hinzuzufügen.
Adaptimmune is presenting at ASCO, potentially providing updates on their drug development projects. Their pipeline includes Afami-cel, which has shown promising results in solid tumors, and Lete-cel, targeting soft tissue sarcoma. Adaptimmune Therapeutics has a reasonable financial position with $144 million in cash, but the termination of a collaboration deal with Genentech poses a risk. Expe...
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Juli Miller – Investor Relations Adrian Rawcliffe – Chief Executive Officer Dennis Williams – Senior Vice President-Late Stage Development Elliot Norry – Chief Medical Officer Jo Brewer – Chief Scientific Officer Gavin Wood – Chief Financial Officer Conference Call Parti...
Adaptimmune Therapeutics is a biotechnology company focused on developing cell therapies for solid tumors. Their afami-cel therapy has demonstrated signs of activity in patients with heavily pretreated sarcoma, with a 2-year rate of overall survival of 70%. The company also has other promising therapies in development, including ADP-A2MCD8 and Lete-cel, targeting different types of cancers.
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q2 2023 Results Conference Call August 9, 2023 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, Late Stage Development Elliot Norry - Chief Medical Officer Gavin Wood - Chief Financial Officer Conference Call Participants Tony Butler - EF Hutton Marc Fr...
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2023 Earnings Conference Call May 12, 2023 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, Late Stage Development Helen Tayton-Martin - Chief Business & Strategy Officer Joanna Brewer - Chief Scientific Officer John Lunger - Chief Patient Suppl...
GSK gave Adaptimmune nearly $37 million as part of a rights deal. Adaptimmune said it expects to launch its first marketed therapy, possibly as soon as the end of this year.
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.